AriBio Reports AR1001 Slows Alzheimer's Decline in Phase 3 Trial
At the 2026 CTAD conference, AriBio reported that its oral drug candidate AR1001 slowed cognitive decline by 31% in early Alzheimer's patients when used as a monotherapy. However, the drug did not achieve statistically significant results in the overall trial population.

Original image temporarily unavailable
AriBio presented data from its Phase 3 POLARIS-AD trial at the Clinical Trials on Alzheimer’s Disease conference, evaluating the oral drug candidate AR1001. The trial randomized 1,535 early Alzheimer's patients to receive AR1001 or placebo daily for 52 weeks.
The study utilized dual primary endpoints. While the overall population showed a non-significant 7% slowing of decline, a prespecified subpopulation of 604 patients receiving AR1001 as monotherapy achieved a 31% slowing of clinical decline compared to placebo. AR1001 works by inhibiting PDE5, aiming to protect neurons and increase blood flow, and showed favorable trends on secondary cognitive measures without the brain swelling risks linked to some anti-amyloid therapies.
View selection rationale
Importance 75/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.